Cipla to pump $89M into building South African biosimilars plant

Subhanu Saxena, CEO of Cipla Pharma of India.
Saxena headshot
Subhanu Saxena

India’s Cipla said it will invest $89 million (1.3 billion rand) to build a new production facility in South Africa that will focus on the manufacturing of biosimilars.

The plant, which is being touted at the first bio-cluster facility on the African continent, will produce biosimilar drugs made from living organisms that would be used in the treatment of cancer and other diseases. Construction is expected to start early next year, with full operations likely to begin by 3Q 2018, The Financial Express reported.

The company’s CEO, Subhanu Saxena, told the newspaper that the manufacturing base in South Africa will give the company opportunities for supply chain partners and related companies to become involved in the market.


Using AI and RWD to Uncover Rare Disease Insights, Accelerate Commercialization and Improve Patient Outcomes

Wednesday, March 24 | 2pm ET / 11am PT

Learn how transformed real world data into real world insights to assist Audentes in their development of AT132 for the treatment of XLMTM. The session reviews how IPM.ia and Audentes collaborated to uncover the XLMTM patient population.

The site for the plant wasn’t cited in the Express story.

Earlier this year, Cipla entered the U.S. market when it acquired a 350,000-square-foot manufacturing plant in Long Island as part of its $550 million buyout of InvaGen Pharmaceuticals, a Hauppauge, NY-based generics maker with 32 products on the market and 30 in the pipeline. Cipla also acquired Exelan Pharmaceuticals, a Lawrenceville, GA, operation that markets and sells InvaGen products into the government and institutional markets.

- check out the Express story

Related Articles: 
Cipla secures first U.S. manufacturing plant